NEW YORK (GenomeWeb News) — Inverness Medical Innovations today said it has commenced its tender offer to buy all of Biosite's outstanding shares at a price of $92.50 per share without interest.
 
Under the cash deal, Inverness would pay an additional $.015205 per share for each day after July 2 that the shares are not accepted for payment.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.